Skip to main content
Clinical Trials/TCTR20190722005
TCTR20190722005
Recruiting
Phase 3

The efficacy and safety of 0.5% topical timolol on corneometry and transepidermal water loss after ablative fractional CO2 laser for atrophic acne scars: a split face randomized double blind placebo-controlled trial

none0 sites25 target enrollmentStarted: July 22, 2019Last updated:

Overview

Phase
Phase 3
Status
Recruiting
Sponsor
none
Enrollment
25

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to 50 Years (—)
Sex
All

Inclusion Criteria

  • The participants aged 18\-50 years old with atrophic area scars for at least three months

Exclusion Criteria

  • 1\) pregnant/lactating female, 2\) history of isotretinoin use within previous 3 months before enrollment, 3\) history of cosmetic procedures including botulinum toxin, filler, collagen, lasers within the preceding 3 months, 4\) history of photosensitivity or skin cancer, 5\) history of psoriasis, hypertension, or asthma, 6\) allergy to anesthetic agents, or timolol solution, 7\) active dermatitis or herpes infection (within previous 2 weeks), 8\) Fitzpatrick skin type V †VI, 9\) current or history of previous use within one month of anticoagulative drugs or NSAIDs use or previous use

Investigators

Sponsor
none

Similar Trials